Sopharma AD notifies that on 25 June 2018 Sopharma AD received an approval from the FSC of the Contract for transformation through merger of Unipharm AD in Sopharma AD and reports of the boards of directors and the independent evaluators. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0.957502, meaning that one share of Unipharm AD will be exchanged for 0.957502 shares of Sopharma AD from the treasury shares available to the receiving company.
The terms and conditions of the merger are available in detail in the Contract for transformation through merger and the reports of the boards of directors and the independent evaluators which are subject to approval by the general meetings of shareholders of both companies. The procedures for convening general meetings for both companies will be initiated on 1 August 2018 .